StemCells, Inc. to Present at Leading Conference on Neuroregeneration in Barcelona
October 22, 2013 09:00 ET
|
StemCells, Inc.
NEWARK, Calif., Oct. 22, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), the leading stem cell company developing novel cell-based therapeutics for disorders of the central nervous system,...
StemCells, Inc. Announces Results of Long-Term Follow-Up Study in Batten Disease
October 21, 2013 09:00 ET
|
StemCells, Inc.
NEWARK, Calif., Oct. 21, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today the results of a four-year observation study in patients with neuronal ceroid lipofuscinosis (NCL), also...
StemCells, Inc. Announces Investigators From Two Clinical Trials to Present at Congress of Neurological Surgeons Annual Meeting
October 17, 2013 09:00 ET
|
StemCells, Inc.
NEWARK, Calif., Oct. 17, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), the leading stem cell company developing novel cell-based therapeutics for disorders of the central nervous system,...
StemCells, Inc. Executive Vice President Ann Tsukamoto, Ph.D., to Make Keynote Address at 2013 Stem Cell Meeting on the Mesa's Scientific Symposium
October 10, 2013 09:00 ET
|
StemCells, Inc.
NEWARK, Calif., Oct. 10, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), the leading stem cell company developing novel cell-based therapeutics for disorders of the central nervous system,...
StemCells, Inc. to Present at 2013 Stem Cell Meeting on the Mesa's Regen Med Partnering Forum
October 09, 2013 09:00 ET
|
StemCells, Inc.
NEWARK, Calif., Oct. 9, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), the leading stem cell company developing novel cell-based therapeutics for disorders of the central nervous system,...
StemCells, Inc. Announces Closing of $18.6 Million Public Offering
October 08, 2013 09:00 ET
|
StemCells, Inc.
NEWARK, Calif., Oct. 8, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that it has closed its previously announced underwritten public offering of common stock and warrants....
StemCells, Inc. Receives FDA Authorization of IND for Spinal Cord Injury
October 02, 2013 09:00 ET
|
StemCells, Inc.
NEWARK, Calif., Oct. 2, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that the U.S. Food and Drug Administration (FDA) has authorized the Company's Investigational New Drug...
StemCells, Inc. Announces Pricing of Public Offering to Raise $16.2 Million
October 02, 2013 08:14 ET
|
StemCells, Inc.
NEWARK, Calif., Oct. 2, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced the pricing of an underwritten public offering of an aggregate of 11,170,000 units at a public offering...
StemCells, Inc. Announces Proposed Public Offering of Common Stock and Warrants
October 01, 2013 16:35 ET
|
StemCells, Inc.
NEWARK, Calif., Oct. 1, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that it intends to offer and sell common stock and warrants, subject to market and other conditions, in...
StemCells, Inc. Announces New Preclinical Data Showing HuCNS-SC(R) Cells Preserve Visual Function by Keeping Photoreceptors Normal and Healthy
September 18, 2013 09:00 ET
|
StemCells, Inc.
NEWARK, Calif., Sept. 18, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced the publication of preclinical data confirming that the Company's proprietary HuCNS-SC cells (purified...